This trial is testing the safety and effectiveness of combining three drugs to treat rare blood cancers.
- Isocitrate Dehydrogenase Mutation
- IDH2 Gene Mutation
- Myeloproliferative Neoplasms
- Isocitrate Dehydrogenase 1 Mutation
- Blood Cancer
2 Primary · 3 Secondary · Reporting Duration: 24 months
2 Treatment Groups
Arm B - Participants with IDH2 Mutations
1 of 2
Arm A - Participants with IDH1 Mutations
1 of 2
50 Total Participants · 2 Treatment Groups
Primary Treatment: Fedratinib · No Placebo Group · Phase 1
Who is running the clinical trial?
Age 18+ · All Participants · 1 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
Has Fedratinib been given the go-ahead from the FDA?
"In the absence of substantial evidence regarding its safety and efficacy, Fedratinib received a score of 1." - Anonymous Online Contributor
To what ailment is Fedratinib most regularly prescribed?
"Fedratinib has been primarily utilized to treat high-risk IPSS patients. It is also used therapeutically for leukemia, myelocytic and acute primary myelofibrosis as well as idh1 mutation susceptibilities." - Anonymous Online Contributor
Is this trial setting a precedent for similar research?
"Research into Fedratinib began in 2013, and the first trial was conducted by Celgene. After 345 participants were studied, Phase 1 & 2 approval of the drug occurred and now there are 46 live trials for it across 255 cities around 45 nations." - Anonymous Online Contributor
How many participants are included in this research endeavor?
"Affirmative. Online records on clinicaltrials.gov verify that this study is presently recruiting individuals, beginning with its initial posting in October 2021 and most recently edited in November of the same year. Fifty participants are needed at only one site for enrollment." - Anonymous Online Contributor
Are there current opportunities for volunteers to participate in this research?
"As indicated by clinicaltrials.gov, this medical research is actively seeking participants. The study was first publicised on October 29th 2021 and has been amended as recently as November 12th 2021" - Anonymous Online Contributor
What other experiments have been conducted with Fedratinib?
"Currently, Fedratinib is the subject of 46 distinct clinical trials. 5 of these are in their final phase 3 stage and 1523 locations across the world offer this treatment to patients. The majority of trial sites for Fedratinib are located in Edmonton, Alberta." - Anonymous Online Contributor